Lung cancer with mediastinal lymph node metastasis can be treated, and there are many ways to treat it. Mediastinal lymph node metastasis of lung cancer often causes enlarged lymph nodes to compress surrounding tissues such as airway and superior vena cava and threaten patients’ lives, for example, small cell lung cancer chemotherapy for superior vena cava syndrome can achieve 80% symptom relief rate. In terms of small molecule targeted therapy, for patients with non-small cell lung cancer with EGFR mutation in the presence of driver genes, they can be treated with gefitinib, erlotinib, erlotinib, afatinib, with an efficiency rate of 60%-80%. If there is ALK fusion gene, ROS1 gene rearrangement, C-MET gene amplification, treatment with crizotinib is available, and the efficiency can reach more than 70%. Surgically, lung cancer with mediastinal lymph node metastasis and compression of airway and superior vena cava has been considered as a contraindication to surgery in the past. With the advancement of surgical operation, surgery has become an irreplaceable treatment to release the compression method. Interventional treatment by tracheal or endovascular interventions, such as placement of endotracheal stents, as well as endovascular balloon dilation and endoluminal stent implantation, are also new methods of relieving lymph nodes from external pressure on airways and blood vessels that have emerged rapidly in recent years. General treatment with oxygen and high-dose glucocorticoids is useful in relieving local inflammation and edema.